We show that PI3K/AKT activating mutations in melanoma do not enable proliferative escape in response to combination BRAF and MEK inhibition, but rather allow the survival of a dormant sub-population of MAPK-inhibited tumour cells, that remain under selective pressure to reactivate MAPK signalling. The gene discussed is AKT1; the disease is melanoma.